Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists in type 2 diabetes, has started phase III trials. If it reaches the market, the oral formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback